ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2025
Integrative Management of High-Risk Proliferative Diabetic Retinopathy: Precision Diagnostics via Ultra-Widefield Imaging and Therapeutic Strategies.
Review in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CD36 Regulates PANoptosis in Diabetic Retinopathy via the NOTCH/MAML Pathway.Journal of diabetes research · 2026Article
- Antibody-based therapeutics and therapeutic development for diabetic retinopathy: targeting VEGF, Ang/Tie, and inflammatory pathways.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy (DR) is a leading cause of blindness worldwide. High-risk proliferative diabetic retinopathy (HR-PDR) is an advanced stage and carries a nearly 50% risk of severe vision loss within five years without intervention. Recent advances in ultra-widefield (UWF) imaging technologies enable comprehensive detection of peripheral lesions and facilitate more accurate diagnosis of disease severity, yet standardized quantitative biomarkers for predicting disease progression remain lacking. Current treatments, including pan-retinal photocoagulation (PRP), anti-vascular endothelial growth factor (anti-VEGF) agents, and pars plana vitrectomy (PPV), demonstrate varying levels of efficacy. There is currently no consensus on the optimal treatment regimen for HR-PDR. Therefore, this review analyzes the application value of UWF imaging in HR-PDR, compares the efficacy of different treatment regimens, and considers their cost-effectiveness and practical applicability meanwhile. Using UWF color fundus photography (CFP) combined with widefield swept-source optical coherence tomography angiography (WF-SS-OCTA) may enhance diagnostic and monitoring outcomes for HR-PDR. Anti-VEGF injections followed PRP could provide stable and sustained protective effects; early PPV may improve outcomes in select cases. Future research should prioritize addressing current research gaps, including the identification of optimal anti-VEGF/PRP protocols, strategies to overcome long-term adherence challenges, establishment of consistent retreatment criteria, clarification of surgical indications, and development of socioeconomic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.